Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03859739
Recruitment Status : Recruiting
First Posted : March 1, 2019
Last Update Posted : October 21, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE February 28, 2019
First Posted Date  ICMJE March 1, 2019
Last Update Posted Date October 21, 2019
Actual Study Start Date  ICMJE April 26, 2019
Estimated Primary Completion Date March 7, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 28, 2019)
  • Change from Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration [ Time Frame: Baseline and 168 hours post-dose ]
    The mean change from baseline in plasma HIV-1 RNA concentration will be assessed.
  • Number of Participants experiencing ≥1 Adverse Event (AE) [ Time Frame: Up to 35 days post-dose ]
    The number of participants experiencing ≥1 AE will be reported.
  • Number of Participants who Discontinue From the Study Due to an Adverse Event (AE) [ Time Frame: Up to 35 days post-dose ]
    The number of participants who discontinue from the study due to an AE will be reported.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03859739 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2019)
  • Area Under the Concentration-Time Curve from 0 to 168 hours (AUC0-168) for MK-8558 in Plasma [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168 hours post-dose ]
    The AUC0-168 for MK-8558 in plasma will be calculated.
  • Area Under the Concentration-Time Curve from 0 up to the Last Quantifiable Time-Point (AUC0-last) for MK-8558 in Plasma [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    The AUC0-last for MK-8558 in plasma will be calculated.
  • Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) for MK-8558 in Plasma [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    The AUC0-inf for MK-8558 in plasma will be calculated.
  • Maximum Observed Concentration (Cmax) for MK-8558 in Plasma [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    The Cmax for MK-8558 in plasma will be reported.
  • Time to Maximum Observed Concentration (Tmax) for MK-8558 in Plasma [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    The Tmax for MK-8558 in plasma will be reported.
  • Concentration at 168 Hours Post-Dose (C168hr) for MK-8558 in Plasma [ Time Frame: 168 hours post-dose ]
    The C168hr for MK-8558 in plasma will be reported.
  • Apparent Clearance (CL/F) for MK-8558 [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    CL/F for MK-8558 will be calculated.
  • Apparent Volume of Distribution (Vz/F) for MK-8558 [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    Vz/F for MK-8558 will be calculated.
  • Terminal Half Life (t1/2) for MK-8558 [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, 168, 240, 336, 504 hours post-dose ]
    t1/2 for MK-8558 will be calculated.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
Official Title  ICMJE A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants
Brief Summary The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-naïve HIV-1 infected participants. The primary hypothesis is that at a dose that exhibits an acceptable safety and tolerability profile, MK-8558 has superior anti-retroviral activity compared to historical placebo data.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV-1 Infection
Intervention  ICMJE Drug: MK-8558
Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
Study Arms  ICMJE
  • Experimental: Panel A. MK-8558 400 mg
    Single oral dose of MK-8558 administered at 400 mg.
    Intervention: Drug: MK-8558
  • Experimental: Panel B. MK-8558 at dose level 2
    Single oral dose of MK-8558 administered at dose level 2. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
    Intervention: Drug: MK-8558
  • Experimental: Panel C. MK-8558 at dose level 3
    Single oral dose of MK-8558 administered at dose level 3. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
    Intervention: Drug: MK-8558
  • Experimental: Panel D. MK-8558 at dose level 4
    Single oral dose of MK-8558 administered at dose level 4. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
    Intervention: Drug: MK-8558
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 28, 2019)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 7, 2020
Estimated Primary Completion Date March 7, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Other than having HIV infection, is in good health based on medical history, physical examination, vital sign (VS) measurements, and laboratory safety tests, at the pre-study (screening) visit and/or prior to administration of the study drug
  • Is documented as being HIV-1 positive
  • Has a screening plasma HIV-1 RNA ≥ 2,500 copies/mL within 30 days prior to the treatment phase of this study
  • Has a screening plasma CD4+ T-cell count of >200/mm^3
  • Is antiretroviral therapy (ART)-naïve
  • Is willing to receive no other ART prior to Day 11 post-dose of the trial, unless the physician/Investigator believes that there is a strong indication to start ART before Day 11
  • Has a Body Mass Index (BMI) ≤35 kg/m^2
  • Males must agree to abstinence, or barrier contraception plus partner contraception, unless confirmed to be azoospermic due to vasectomy or medical cause, for at least 35 days after the last dose of MK-8558
  • Females must not be pregnant or breastfeeding, and must be a woman of nonchildbearing potential, or a woman of childbearing potential using highly effective birth control with low user dependency or who is abstinent on a long-term and persistent basis during the intervention period and at least 35 days after the last dose of study medication

Exclusion Criteria:

  • Has acute (primary) HIV-1 infection
  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic (with the exception of Gilbert's disease), immunological (outside of HIV-1 infection), renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated or has a history of a clinically significant psychiatric disorder (with the exception of situational depression) of the last 5 years
  • Has a history of cancer unless disease is adequately treated and deemed "cured"
  • Has an estimated creatinine clearance (CrCl) ≤ 90 mL/min
  • Has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food, or has hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
  • Is positive for hepatitis B surface antigen
  • Has a history of chronic hepatitis C unless there has been documented cure
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-study (screening) visit
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study, until the post-study visit. There may be certain medications that are permitted
  • Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the pre-study (screening) visit. The window will be derived from the date of the last visit in the previous study
  • Is under the age of legal consent or not capable of giving consent
  • Has been committed to an institution by way of official or judicial order
  • Is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day
  • Consumes more than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day. Participants who consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator
  • Consumes excessive amounts, defined as more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Has a positive urine drug screen (except for cannabis) at screening and/or pre-dose; rechecks are allowed
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03859739
Other Study ID Numbers  ICMJE 8558-002
MK-8558-002 ( Other Identifier: Merck Protocol Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP